<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Buspirone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Buspirone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Buspirone: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9172" href="/d/html/9172.html" rel="external">see "Buspirone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11517" href="/d/html/11517.html" rel="external">see "Buspirone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866139"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-BusPIRone;</li>
<li>AURO-Buspirone;</li>
<li>CO BusPIRone;</li>
<li>GMD-Buspirione;</li>
<li>JAMP-Buspirone;</li>
<li>MINT-Buspirone;</li>
<li>PMS-BusPIRone;</li>
<li>TEVA-BusPIRone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051430"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianxiety Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812484"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e83bc66-3e6e-49b3-ab21-449ee2b4f882">Anxiety disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety disorders:</b> Children ≥6 years and Adolescents: Limited data available; dose and efficacy not well established: Oral: Initial dose: 5 mg once daily; may increase by 5 mg/day every 2 to 7 days as tolerated; usual dose range: 7.5 to 30 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simeon.1','lexi-content-ref-28846022','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simeon.1','lexi-content-ref-28846022','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on open-label and placebo-controlled trials. One open pilot study of 15 children (mean age: 10 years [range: 6 to 14 years]) with mixed anxiety disorders (per DSM III-R criteria) used an initial dose of 5 mg daily; doses were titrated by increments of 5 mg/day every week as needed to a maximum dose of 20 mg/day divided into 2 doses; mean dose required: 18.6 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simeon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simeon.1'])">Ref</a></span>). Two placebo-controlled 6-week trials in children and adolescents (n=559; age: 6 to 17 years) with generalized anxiety disorder evaluated doses of 7.5 to 30 mg twice daily (15 to 60 mg/day); no significant differences between buspirone and placebo with respect to generalized anxiety disorder symptoms were observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). A 2018 analysis of these abandoned trials reported that buspirone did not separate from placebo; however, the studies may have been underpowered to detect small differences, suggesting that the studies neither support nor refute the utility of buspirone. The dropout rate due to adverse reactions in the studies was higher for buspirone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28846022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28846022'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729614"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Patients with impaired renal function demonstrated increased plasma levels and a prolonged half-life of buspirone. Use in patients with severe renal impairment not recommended.</p></div>
<div class="block dohp drugH1Div" id="F52729615"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Patients with impaired hepatic function demonstrated increased plasma levels and a prolonged half-life of buspirone. Use in patients with severe hepatic impairment not recommended.</p></div>
<div class="block doa drugH1Div" id="F143299"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9172" href="/d/html/9172.html" rel="external">see "Buspirone: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder:</b> Oral: Initial: 10 to 15 mg/day in 2 to 3 divided doses; may increase every 2 to 3 days in increments of 5 mg/day to a maximum of 60 mg/day; usual dose: 20 to 30 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16856115','lexi-content-ref-10356651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16856115','lexi-content-ref-10356651'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d4fcd59-13df-41e2-99be-000967883ea1">Shivering, targeted temperature management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shivering, targeted temperature management (adjunctive agent) (off-label use): Note: </b>Consider as an adjunctive agent as part of a shivering protocol in patients undergoing targeted temperature management post-cardiac arrest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21210305','lexi-content-ref-34498206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21210305','lexi-content-ref-34498206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>30 mg every 8 hours during the cooling phase of targeted temperature management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21210305','lexi-content-ref-34498206','lexi-content-ref-11682404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21210305','lexi-content-ref-34498206','lexi-content-ref-11682404'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98eae463-6384-48da-912e-db999bc02298">Unipolar depression, augmentation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unipolar depression, augmentation (alternative agent following antidepressant switch and other augmentation agents) (off-label use):</b> Oral: Initial: 15 to 20 mg/day in 2 divided doses; may increase every 3 to 7 days in increments of 10 to 15 mg/day to a maximum of 60 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-11465522','lexi-content-ref-16554526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-11465522','lexi-content-ref-16554526'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991629"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;60 mL/minute: No specific dose adjustments can be recommended due to the high interindividual variability in reported AUC and half-life of buspirone and its active metabolite; however, mean plasma concentrations of buspirone and its active metabolite are significantly elevated compared to subjects with normal kidney function. Thus, it is reasonable to start with low daily doses (eg, 5 mg twice daily); titrate cautiously based on response and tolerability with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7911763','lexi-content-ref-3370902','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7911763','lexi-content-ref-3370902','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (86% protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">No specific dose adjustments can be recommended due to the high interindividual variability in reported AUC and half-life of buspirone and its active metabolite; however, mean plasma concentrations of buspirone and its active metabolite are significantly elevated in patients on hemodialysis compared to subjects with normal kidney function. Thus, it is reasonable to start with low daily doses (eg, 2.5 to 5 mg twice daily); titrate cautiously based on response and tolerability with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7911763','lexi-content-ref-3370902','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7911763','lexi-content-ref-3370902','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Limiting the total daily dose to 30 to 45 mg/day has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3370902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3370902'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (86% protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">No specific dose adjustments can be recommended due to the high interindividual variability in reported AUC and half-life of buspirone and its active metabolite; however, mean plasma concentrations of buspirone and its active metabolite are significantly elevated in patients with end-stage kidney disease compared to subjects with normal kidney function. Thus, it is reasonable to start with low daily doses (eg, 2.5 to 5 mg twice daily); titrate cautiously based on response and tolerability with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7911763','lexi-content-ref-3370902','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7911763','lexi-content-ref-3370902','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Limiting the total daily dose to 30 to 45 mg/day has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3370902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3370902'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b> Use with caution (has not been studied); interindividual pharmacokinetic variability is likely significant, and critically ill patients may have concomitant liver dysfunction and altered protein binding. Start with low daily doses (eg, 5 mg twice daily); titrate cautiously based on response and tolerability with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Use with caution (has not been studied); interindividual pharmacokinetic variability is likely significant, and critically ill patients may have concomitant liver dysfunction and altered protein binding. Start with low daily doses (eg, 5 mg twice daily); titrate cautiously based on response and tolerability with close monitoring for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988916"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (these patients demonstrated increased plasma levels and a prolonged half-life of buspirone).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use not recommended.</p></div>
<div class="block arsc drugH1Div" id="F55642960"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although CNS effects are uncommon with use, with the possible exception of <b>dizziness</b>, buspirone has been associated with some mild to moderate CNS effects such as <b>headache</b>, <b>nervousness</b>, <b>excitement</b>, and to a lesser degree, <b>drowsiness</b> and <b>insomnia</b>. Data suggest that stimulant effects (eg, nervousness, dizziness, excitement) are more likely to occur than sedative effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1883000','lexi-content-ref-6130065','lexi-content-ref-2870641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1883000','lexi-content-ref-6130065','lexi-content-ref-2870641'])">Ref</a></span>). Data also suggest that buspirone has limited effects on performance function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1822316','lexi-content-ref-9234037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1822316','lexi-content-ref-9234037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; mechanism has not been fully elucidated, but it is believed that buspirone acts as a serotonin (5-HT<sub>1A</sub>) partial agonist and has moderate affinity for dopamine D<sub>2</sub> receptors in the brain. Buspirone has been shown to increase the spontaneous firing of noradrenergic neurons in the locus ceruleus in a dose-dependent manner, stimulating central sympathomimetic activity (and suggesting that it does not possess a strong sedative potential) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19288084','lexi-content-ref-9826102','lexi-content-ref-2873889','lexi-content-ref-1883000','lexi-content-ref-1573045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19288084','lexi-content-ref-9826102','lexi-content-ref-2873889','lexi-content-ref-1883000','lexi-content-ref-1573045'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced movement disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Buspirone has been associated with rare cases of drug-induced movement disorders, including <b>dyskinesia</b>, <b>akathisia</b>, <b>dystonia</b> (usually focal), <b>myoclonus</b>, and <b>parkinsonism</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2247245','lexi-content-ref-12549947','lexi-content-ref-8101969','lexi-content-ref-3379031','lexi-content-ref-32191616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2247245','lexi-content-ref-12549947','lexi-content-ref-8101969','lexi-content-ref-3379031','lexi-content-ref-32191616'])">Ref</a></span>). In the majority of the parkinsonism cases, patients had a previous diagnosis of Parkinson disease. Of the buspirone-associated movement disorders reported, dyskinesia and akathisia appear to be the most commonly reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Although buspirone's mechanism of action is complex and not fully elucidated, it is believed to display high affinity for serotonin type 1A (5-HT<sub>1A</sub>) receptors where it acts as a partial agonist. It is also thought to have weak affinity for serotonin 5-HT<sub>2</sub> receptors. In addition, it affects the dopaminergic pathway, where it is thought to act as a moderate antagonist at central dopamine D<sub>2</sub> autoreceptors, resulting in increased firing rates and increasing dopamine levels in the synapse. It has also been suggested to display a "post synaptic dopamine antagonist-like effect," decreasing stimulation of the postsynaptic dopamine receptors. Its effects on dopamine may be dose dependent. Lastly, buspirone is believed to produce dose-dependent stimulation of the noradrenergic neurons of the locus ceruleus. In the various buspirone-associated movement disorders reported, buspirone-induced akathisia has been hypothesized to be attributed to buspirone's effect on noradrenergic neurotransmission; myoclonus and dystonia to its serotonin effects; and dyskinesia and parkinsonism to its dopaminergic-serotoninergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12549947','lexi-content-ref-2873889','lexi-content-ref-32191616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12549947','lexi-content-ref-2873889','lexi-content-ref-32191616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in a literature review, the mean onset to a buspirone-associated movement disorder was 4.6 weeks and the median onset was 4 weeks (range: 1 day to 21 weeks). In the majority of cases (76%), onset was within 1 month. The time to complete recovery following buspirone withdrawal was within 1 month in the majority of cases (88%). Most cases resolved following discontinuation, but in a couple of cases the symptoms continued after buspirone withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Parkinsonism: Higher doses (ie, twice the average dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12549947','lexi-content-ref-2873889','lexi-content-ref-32191616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12549947','lexi-content-ref-2873889','lexi-content-ref-32191616'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been associated with buspirone when co-administered with another or multiple serotonergic agents, such as selective serotonin receptor inhibitors (SSRIs), particularly fluoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8548727','lexi-content-ref-15784664','lexi-content-ref-12503845','lexi-content-ref-1557493','lexi-content-ref-10928399','lexi-content-ref-9179637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8548727','lexi-content-ref-15784664','lexi-content-ref-12503845','lexi-content-ref-1557493','lexi-content-ref-10928399','lexi-content-ref-9179637'])">Ref</a></span>). There is also a case report of serotonin syndrome possibly occurring with buspirone and linezolid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22452676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22452676'])">Ref</a></span>). Because buspirone is a partial serotonin agonist, some authors have questioned its potential to cause serotonin syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19925619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19925619'])">Ref</a></span>); however, reports of serotonin syndrome have been documented with buspirone at therapeutic doses when combined with other serotonergic agents. The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; serotonin syndrome can arise with any agent that directly or indirectly increases central serotonin neurotransmission at postsynaptic 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14970364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14970364'])">Ref</a></span>). Buspirone has been shown to have high affinity for serotonin 5-HT<sub>1A </sub>receptors<sub>, </sub>where it acts as a partial agonist, and has weak affinity for serotonin 5-HT<sub>2</sub> receptors, and has variable effects on post- and presynaptic serotonin receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8548727','lexi-content-ref-12503845','lexi-content-ref-19925619','lexi-content-ref-10928399','lexi-content-ref-22452676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8548727','lexi-content-ref-12503845','lexi-content-ref-19925619','lexi-content-ref-10928399','lexi-content-ref-22452676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid (usually); in general, most cases of serotonin syndrome with a serotonergic agent occur within 24 hours of treatment initiation, overdose, or change in dose. In some patients, mild symptoms may be present for weeks before progressing to a more severe form of the syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10928399','lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10928399','lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F143264"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Dizziness (3% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Buspirone: Adverse Reaction: Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-buspirone-adverse-reaction-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-buspirone-adverse-reaction-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Buspirone: Adverse Reaction: Dizziness</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Buspirone: Adverse Reaction: Dizziness" frame="border" id="lexi-content-buspirone-adverse-reaction-dizziness" rules="all">
<caption style="text-align:center;">
<b>Buspirone: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lightheadedness</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cold and clammy skin (≤1%), diaphoresis (≤1%), skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (2%), nausea (8%), sore throat (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (≥1%), ataxia (1%), confusion (2%), drowsiness (10%)<span class="lexi-table-link-container"> (<a aria-label="Buspirone: Adverse Reaction: Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-buspirone-adverse-reaction-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-buspirone-adverse-reaction-drowsiness')">table 2</a>)</span><span class="table-link" style="display:none;">Buspirone: Adverse Reaction: Drowsiness</span>, excitement (2%)<span class="lexi-table-link-container"> (<a aria-label="Buspirone: Adverse Reaction: Excitement table link" class="lexi-table-link" data-table-id="lexi-content-buspirone-adverse-reaction-excitement" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-buspirone-adverse-reaction-excitement')">table 3</a>)</span><span class="table-link" style="display:none;">Buspirone: Adverse Reaction: Excitement</span>, headache (6%)<span class="lexi-table-link-container"> (<a aria-label="Buspirone: Adverse Reaction: Headache table link" class="lexi-table-link" data-table-id="lexi-content-buspirone-adverse-reaction-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-buspirone-adverse-reaction-headache')">table 4</a>)</span><span class="table-link" style="display:none;">Buspirone: Adverse Reaction: Headache</span>, hostility (≤2%), insomnia (3% to 4% [Newton 1986a])<span class="lexi-table-link-container"> (<a aria-label="Buspirone: Adverse Reaction: Insomnia table link" class="lexi-table-link" data-table-id="lexi-content-buspirone-adverse-reaction-insomnia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-buspirone-adverse-reaction-insomnia')">table 5</a>)</span><span class="table-link" style="display:none;">Buspirone: Adverse Reaction: Insomnia</span>, nervousness (5%)<span class="lexi-table-link-container"> (<a aria-label="Buspirone: Adverse Reaction: Nervousness table link" class="lexi-table-link" data-table-id="lexi-content-buspirone-adverse-reaction-nervousness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-buspirone-adverse-reaction-nervousness')">table 6</a>)</span><span class="table-link" style="display:none;">Buspirone: Adverse Reaction: Nervousness</span>, numbness (2%), outbursts of anger (≤2%), paresthesia (1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Buspirone: Adverse Reaction: Drowsiness" frame="border" id="lexi-content-buspirone-adverse-reaction-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Buspirone: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Buspirone: Adverse Reaction: Excitement" frame="border" id="lexi-content-buspirone-adverse-reaction-excitement" rules="all">
<caption style="text-align:center;">
<b>Buspirone: Adverse Reaction: Excitement</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Buspirone: Adverse Reaction: Headache" frame="border" id="lexi-content-buspirone-adverse-reaction-headache" rules="all">
<caption style="text-align:center;">
<b>Buspirone: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Buspirone: Adverse Reaction: Insomnia" frame="border" id="lexi-content-buspirone-adverse-reaction-insomnia" rules="all">
<caption style="text-align:center;">
<b>Buspirone: Adverse Reaction: Insomnia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">984</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">334</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Newton 1986a</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Product labeling</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Buspirone: Adverse Reaction: Nervousness" frame="border" id="lexi-content-buspirone-adverse-reaction-nervousness" rules="all">
<caption style="text-align:center;">
<b>Buspirone: Adverse Reaction: Nervousness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buspirone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">464</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (2%), musculoskeletal pain (≤1%), myalgia (≤1%), tremor (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, bradycardia, cardiac failure, cardiomyopathy, cerebrovascular accident, edema, facial edema, flushing, hypertension, hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, pruritus, skin blister, thinning of nails, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, change in libido, galactorrhea not associated with childbirth, menstrual disease, thyroid disease, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, dysgeusia, flatulence, hiccups, increased appetite, irritable bowel syndrome, salivation</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, impotence, nocturia, pelvic inflammatory disease, spotting, urinary frequency, urinary hesitancy, urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bleeding tendency disorder, bruise, eosinophilia, leukopenia, rectal hemorrhage, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia, alcohol abuse, altered sense of smell, apathy, claustrophobia, cold intolerance, delayed ejaculation, depersonalization, dissociative reaction, dysphoria, euphoria, fear, glossopyrosis, hallucination, hyperacusis, involuntary muscle movements, malaise, psychosis (including exacerbation of psychosis [adult; Pantelis 1993]), roaring sensation in head, seizure, slowed reaction time, slurred speech, stupor, suicidal ideation, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle rigidity, muscle spasm, stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, eye pain, eye pruritus, eye redness, increased intraocular pressure, photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Inner ear disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Chest congestion, dyspnea, epistaxis, hyperventilation, laryngitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cogwheel rigidity, dystonia (Boylan 1990), emotional lability, extrapyramidal reaction, hypomania (Liegghio 1988a), mania (McIvor 1991), memory impairment, neurological deterioration (psychotic deterioration [children; Soni 1992]), parkinsonism (Clay 2003), restless leg syndrome, restlessness (Liegghio 1988b), serotonin syndrome (Baetz 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (LeWitt 1993), myoclonus (Ritchie 1988)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (including tunnel vision)</p></div>
<div class="block coi drugH1Div" id="F143277"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to buspirone or any component of the formulation; concomitant use of monoamine oxidase inhibitors (MAOIs) intended to treat depression or within 14 days of discontinuing MAOIs intended to treat depression; concomitant use of MAOIs within 14 days of discontinuing buspirone; initiation of buspirone in patients receiving reversible MAOIs (eg, linezolid, IV methylene blue).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications not in US labeling: Severe hepatic or severe renal impairment.</p></div>
<div class="block war drugH1Div" id="F143261"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with hepatic impairment; use in severe hepatic impairment is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sedative/hypnotic withdrawal: Buspirone does not exhibit cross-tolerance with benzodiazepines or other sedative/hypnotic agents. If substituting buspirone for any of these agents, gradually withdraw the drug(s) prior to initiating buspirone.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878358"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Buspirone does not possess antipsychotic activity and should not be used in place of appropriate antipsychotic treatment; two pediatric cases of possible psychotic deterioration have been reported (Soni 1992).</p></div>
<div class="block foc drugH1Div" id="F143271"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg</p></div>
<div class="block geq drugH1Div" id="F143257"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F143280"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (busPIRone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.15 - $0.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $1.09 - $1.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.21 - $1.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.65 - $2.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $3.63 - $3.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866140"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block admp drugH1Div" id="F52612333"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer in a consistent manner in relation to food (ie, either always with food or always without food).</p></div>
<div class="block adm drugH1Div" id="F16136510"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food, but must be consistent.</p></div>
<div class="block sts drugH1Div" id="F5628405"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53565752"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of anxiety disorders or short-term relief of anxiety symptoms (FDA approved in ages ≥6 years and adults).</p></div>
<div class="block mst drugH1Div" id="F143346"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">BusPIRone may be confused with buPROPion</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F143331"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F143266"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): BusPIRone may enhance the sedative effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of BusPIRone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of BusPIRone. Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of BusPIRone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of BusPIRone. Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors. Dose adjustments of buspirone or a strong CYP3A4 inhibitor should be based on clinical assessment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of BusPIRone. Management: Limit the buspirone dose to 2.5 mg twice daily and monitor for increased buspirone effects/toxicities if combined with erythromycin. Dose adjustments of buspirone or erythromycin should be based on clinical assessments.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of BusPIRone. Management: Patients should avoid consuming large quantities of grapefruit juice during use of buspirone. If patients consume grapefruit juice during buspirone therapy, monitor for increased buspirone adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: BusPIRone may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: BusPIRone may enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: BusPIRone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): BusPIRone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: BusPIRone may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities, including serotonin syndrome, if combined with nefazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: May enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Resveratrol: May increase the serum concentration of BusPIRone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): BusPIRone may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: BusPIRone may enhance the serotonergic effect of St John's Wort. This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of BusPIRone.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and for reduced buspirone efficacy when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F143290"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food may decrease the absorption of buspirone, but it may also decrease the first-pass metabolism, thereby increasing the bioavailability of buspirone. Grapefruit juice may cause increased buspirone concentrations. Management: Administer with or without food, but must be consistent. Avoid intake of large quantities of grapefruit juice. </p></div>
<div class="block dic drugH1Div" id="F9460172"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid large quantities of grapefruit juice.</p></div>
<div class="block pri drugH1Div" id="F5628102"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Limited outcome data following maternal use of buspirone are available from the National Pregnancy Registry for Psychiatric Medications, a prospective study of patients taking psychiatric medications during the first trimester of pregnancy (68 women, 72 infants) (Freeman 2022), and postmarketing data collected following the initial release of buspirone (16 first trimester exposures) (Wilton 1998).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated anxiety in pregnant patients is associated with adverse maternal, fetal, and neonatal outcomes. Treatment of anxiety disorders during pregnancy should include the patient as part of a shared decision-making process. Due to lack of data, agents other than buspirone are preferred for use during pregnancy. Consider discontinuing buspirone and using alternative therapies during pregnancy unless there is a clear benefit to continuing treatment (Thorsness 2018)</p></div>
<div class="block mopp drugH1Div" id="F53565754"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status, signs and symptoms of anxiety, liver and renal function; signs of dopamine-related movement disorders (eg, dystonia, akathisia, pseudo-parkinsonism).</p></div>
<div class="block pha drugH1Div" id="F143260"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanism of action of buspirone is unknown. Buspirone has a high affinity for serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptors, without affecting benzodiazepine-GABA receptors. Buspirone has moderate affinity for dopamine D<sub>2</sub> receptors.</p></div>
<div class="block phk drugH1Div" id="F143276"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete; bioavailability is limited by extensive first-pass effect; only ~1% of the oral dose reaches the systemic circulation unchanged</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 5.3 L/kg (Gammans 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~86%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic oxidation, primarily via CYP3A4 to several metabolites including an active metabolite, 1-pyrimidinylpiperazine (1-PP; exhibits about 25% of the activity of buspirone); extensive first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Increased with food</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 to 3 hours; increased with renal or hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 40 to 90 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 29% to 63% (primarily as metabolites); feces: 18% to 38%</p></div>
<div class="block phksp drugH1Div" id="F51154187"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased 4-fold.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC increased 13-fold.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F143281"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Buspirone</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ansial | Aristopiron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Anksilon | Buspar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ansitec | Buspanil | Buspar | Cloridrato de buspirona</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Buspirona | Paxon</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Buspirone | Qi bi te | Su xin | Suxin | Yi shu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bonival | Buspar | Buspirona | Nodeprex | Normaton | Serenid | Tutran</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anxiron | Buspiron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anxut | Bespar | Busp | Buspar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ansionax | Buspar | Normaton | Relax | Tutran</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Spitomin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Anxbeat | Buspalex | Buspar | Exupar | Neurobus</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Effiplen | Narol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Anksilon | Buspar | Buspiron alpharma</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Buspirone g gam | Buspirone merck | Buspirone Sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Buspirone | Buspirone cox | Buspirone kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anchocalm | Bergamol | Bespar | Boronex | Buspirone | Epsilat | Hiremon | Hobatstress | Komasin | Lanamont | Lebilon | Ledion | Loxapin | Nadrifor | Nervostal | Nevrorestol | Norbal | Pendium | Stressigal | Svitalark | Tensispes | Umolit</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-Buspirone | Buspar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Anxiron | Spitomin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Tran-q | Xiety</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Buspirol | Sorbon</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Biziron | Buscalm | Buspin | Buspinet | Tamspar</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Exan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Axoren | Buspar | Buspimen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Busirone</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Babron | Boryung buspar | Busone | Buspar | Buspin | Buspine | Buspirone | Busporone | Busron | Busta | Myungin buspirone hcl | Piron | Samsung buspirone | Sbrol | Sburol | Seron | Whanin buspirone | Young poong buspirone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Spitomin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Busp | Spitomin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Buspiron | Buspiron Hcl Actavis | Buspiron hcl alpharma | Buspiron hcl cf | Buspiron hcl merck | Buspiron HCl Sandoz | Buspiron ratiopharm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Busp | Buspar | Buspiron | Buspirone Orion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Biron | Buspar | Buspirone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Benzodep | Buspar | Buspin | Buspro | Busron | Novatil | Spir | Vurinil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Buspirone | Buxal | Mabuson | Spamilan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Buspar First Month | Buspirone HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ansiten | Busansil | Buscalma | Buspar | Buspirona | Buspirona Labesfal | Buspirona orion | Establix | Itagil | Psibeter</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actium | Duvaline</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Spitomin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Pms buspirone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Anksilon | Buspar | Buspiron 2care4 | Buspiron Actavis | Buspiron alpharma | Buspiron ebb | Buspiron Mylan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Buspar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Anxiron | Spitomin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anxiolan | Barpil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anxinil | Anxiron | Buisline | Buslac | Busmin | Busp | Buspam | Buspar | Buspin | Buspine | Buspirone | Busron | Depiron | Relac | Sepirone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Buspiron | Buspiron hexal | Spitomin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ansial | Busparium | Buspine | Nitil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Dalpas</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Buspar | Pasrin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published May 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11465522">
<a name="11465522"></a>Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. <i>J Clin Psychiatry</i>. 2001;62(6):448-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/11465522/pubmed" id="11465522" target="_blank">11465522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8548727">
<a name="8548727"></a>Baetz M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone. <i>Can J Psychiatry</i>. 1995;40(7):428-429. doi:10.1177/070674379504000721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/8548727/pubmed" id="8548727" target="_blank">8548727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911763">
<a name="7911763"></a>Barbhaiya RH, Shukla UA, Pfeffer M, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. <i>Eur J Clin Pharmacol</i>. 1994;46(1):41-47. doi:10.1007/BF00195914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/7911763/pubmed" id="7911763" target="_blank">7911763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome [published correction appears in <i>N Engl J Med</i>. 2007;356(23):2437] [published correction appears in <i>N Engl J Med</i>. 2009;361(17):1714]. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2247245">
<a name="2247245"></a>Boylan K. Persistent dystonia associated with buspirone. <i>Neurology</i>. 1990;40(12):1904. doi:10.1212/wnl.40.12.1904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/2247245/pubmed" id="2247245" target="_blank">2247245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9475699">
<a name="9475699"></a>Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. <i>Clin Pediatr (Phila)</i>. 1998;37(1):41-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/9475699/pubmed" id="9475699" target="_blank">9475699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buspirone.1">
<a name="Buspirone.1"></a>Buspirone [prescribing information]. Sacramento, CA: Nivagen Pharmaceuticals Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buspirone.2">
<a name="Buspirone.2"></a>Buspirone [product monograph]. Weston, Ontario, Canada: Apotex Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3370902">
<a name="3370902"></a>Caccia S, Vigano GL, Mingardi G, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. <i>Clin Pharmacokinet</i>. 1988;14(3):171-177. doi:10.2165/00003088-198814030-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/3370902/pubmed" id="3370902" target="_blank">3370902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16856115">
<a name="16856115"></a>Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. <i>Cochrane Database Syst Rev</i>. 2006;(3):CD006115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/16856115/pubmed" id="16856115" target="_blank">16856115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21210305">
<a name="21210305"></a>Choi HA, Ko SB, Presciutti M, et al. Prevention of shivering during therapeutic temperature modulation: the Columbia anti-shivering protocol. <i>Neurocrit Care</i>. 2011;14(3):389-394. doi:10.1007/s12028-010-9474-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/21210305/pubmed" id="21210305" target="_blank">21210305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12549947">
<a name="12549947"></a>Clay PG, Adams MM. Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. <i>Ann Pharmacother</i>. 2003;37(2):202-205. doi:10.1177/106002800303700207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/12549947/pubmed" id="12549947" target="_blank">12549947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12503845">
<a name="12503845"></a>Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. <i>J Psychopharmacol</i>. 2002;16(4):401. doi:10.1177/026988110201600420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/12503845/pubmed" id="12503845" target="_blank">12503845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35840767">
<a name="35840767"></a>Freeman MP, Szpunar MJ, Kobylski LA, Harmon H, Viguera AC, Cohen LS. Pregnancy outcomes after first-trimester exposure to buspirone: prospective longitudinal outcomes from the MGH National Pregnancy Registry for Psychiatric Medications. <i>Arch Womens Ment Health</i>. 2022;25(5):923-928. doi:10.1007/s00737-022-01250-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/35840767/pubmed" id="35840767" target="_blank">35840767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3515929">
<a name="3515929"></a>Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. <i>Am J Med</i>. 1986;80(3B):41-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/3515929/pubmed" id="3515929" target="_blank">3515929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19925619">
<a name="19925619"></a>Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. <i>Headache</i>. 2010;50(2):264-272. doi:10.1111/j.1526-4610.2009.01575.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/19925619/pubmed" id="19925619" target="_blank">19925619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1557493">
<a name="1557493"></a>Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone. <i>Psychosomatics</i>. 1992;33(2):235-236. doi:10.1016/S0033-3182(92)72007-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/1557493/pubmed" id="1557493" target="_blank">1557493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14970364">
<a name="14970364"></a>Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. <i>Ann Pharmacother</i>. 2004;38(3):411-413. doi:10.1345/aph.1D344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/14970364/pubmed" id="14970364" target="_blank">14970364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34498206">
<a name="34498206"></a>Huynh C, Lui J, Behbahani V, Thompson Quan A, Morris A, Baumgartner L. Pre versus post implementation of a pharmacologic antishivering protocol during targeted temperature management following cardiac arrest. <i>Neurocrit Care</i>. 2022;36(2):511-518. doi:10.1007/s12028-021-01327-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/34498206/pubmed" id="34498206" target="_blank">34498206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19288084">
<a name="19288084"></a>Koudas V, Nikolaou A, Hourdaki E, Giakoumaki SG, Roussos P, Bitsios P. Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers. <i>Psychopharmacology (Berl)</i>. 2009;205(1):1-9. doi:10.1007/s00213-009-1508-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/19288084/pubmed" id="19288084" target="_blank">19288084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826102">
<a name="9826102"></a>Lechin F, van der Dijs B, Jara H, et al. Effects of buspirone on plasma neurotransmitters in healthy subjects. <i>J Neural Transm (Vienna)</i>. 1998;105(6-7):561-573. doi:10.1007/s007020050079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/9826102/pubmed" id="9826102" target="_blank">9826102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8101969">
<a name="8101969"></a>LeWitt PA, Walters A, Hening W, McHale D. Persistent movement disorders induced by buspirone. <i>Mov Disord</i>. 1993;8(3):331-334. doi:10.1002/mds.870080313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/8101969/pubmed" id="8101969" target="_blank">8101969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3379150">
<a name="3379150"></a>Liegghio NE, Yeragani VK. Buspirone-induced hypomania: a case report. <i>J Clin Psychopharmacol</i>. 1988;8(3):226-227. doi:10.1097/00004714-198806000-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/3379150/pubmed" id="3379150" target="_blank">3379150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3356675">
<a name="3356675"></a>Liegghio NE, Yeragani VK, Moore NC. Buspirone-induced jitteriness in three patients with panic disorder and one patient with generalized anxiety disorder. <i>J Clin Psychiatry</i>. 1988;49(4):165-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/3356675/pubmed" id="3356675" target="_blank">3356675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2873889">
<a name="2873889"></a>Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. <i>Clin Neuropharmacol</i>. 1986;9(4):373-378. doi:10.1097/00002826-198608000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/2873889/pubmed" id="2873889" target="_blank">2873889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1883000">
<a name="1883000"></a>Manfredi RL, Kales A, Vgontzas AN, Bixler EO, Isaac MA, Falcone CM. Buspirone: sedative or stimulant effect? <i>Am J Psychiatry</i>. 1991;148(9):1213-1217. doi:10.1176/ajp.148.9.1213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/1883000/pubmed" id="1883000" target="_blank">1883000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10928399">
<a name="10928399"></a>Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. <i>Ann Pharmacother</i>. 2000;34(7-8):871-874. doi:10.1345/aph.19341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/10928399/pubmed" id="10928399" target="_blank">10928399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2015445">
<a name="2015445"></a>McIvor R, Sinanan K. Buspirone-induced mania. <i>Br J Psychiatry</i>. 1991;158:136-137. doi:10.1192/bjp.158.1.136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/2015445/pubmed" id="2015445" target="_blank">2015445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11682404">
<a name="11682404"></a>Mokhtarani M, Mahgoub AN, Morioka N, et al. Buspirone and meperidine synergistically reduce the shivering threshold. <i>Anesth Analg</i>. 2001;93(5):1233-1239. doi:10.1097/00000539-200111000-00038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/11682404/pubmed" id="11682404" target="_blank">11682404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22452676">
<a name="22452676"></a>Morrison EK, Rowe AS. Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia. <i>J Clin Pharm Ther</i>. 2012;37(5):610-613. doi:10.1111/j.1365-2710.2012.01344.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/22452676/pubmed" id="22452676" target="_blank">22452676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19607765">
<a name="19607765"></a>Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. <i>J Clin Psychiatry</i>. 2009;70(9):1304-1310. doi:10.4088/JCP.08m05001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/19607765/pubmed" id="19607765" target="_blank">19607765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6130065">
<a name="6130065"></a>Newton RE, Casten GP, Alms DR, Benes CO, Marunycz JD. The side effect profile of buspirone in comparison to active controls and placebo. <i>J Clin Psychiatry</i>. 1982;43(12 Pt 2):100-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/6130065/pubmed" id="6130065" target="_blank">6130065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2870641">
<a name="2870641"></a>Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. <i>Am J Med</i>. 1986;80(3B):17-21. doi:10.1016/0002-9343(86)90327-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/2870641/pubmed" id="2870641" target="_blank">2870641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1822316">
<a name="1822316"></a>O'Hanlon JF. Review of buspirone's effects on human performance and related variables. <i>Eur Neuropsychopharmacol</i>. 1991;1(4):489-501. doi:10.1016/0924-977x(91)90002-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/1822316/pubmed" id="1822316" target="_blank">1822316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290846">
<a name="22290846"></a>Pantelis C, Barnes TR. Acute exacerbation of psychosis with buspirone? <i>J Psychopharmacol</i>. 1993;7(3):295-300. doi:10.1177/026988119300700311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/22290846/pubmed" id="22290846" target="_blank">22290846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32191616">
<a name="32191616"></a>Rissardo JP, Caprara ALF. Buspirone-associated movement disorder: a literature review. <i>Prague Med Rep</i>. 2020;121(1):5-24. doi:10.14712/23362936.2020.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/32191616/pubmed" id="32191616" target="_blank">32191616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3379031">
<a name="3379031"></a>Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized myoclonus following buspirone administration. <i>J Clin Psychiatry</i>. 1988;49(6):242-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/3379031/pubmed" id="3379031" target="_blank">3379031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9234037">
<a name="9234037"></a>Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. <i>Exp Clin Psychopharmacol</i>. 1997;5(1):28-38. doi:10.1037//1064-1297.5.1.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/9234037/pubmed" id="9234037" target="_blank">9234037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simeon.1">
<a name="Simeon.1"></a>Simeon JG, Knott VJ, DuBois C, et al, “Buspirone Therapy of Mixed Anxiety Disorders in Childhood and Adolescence: A Pilot Study,” <i>J Child Adolesc Psychopharmacol</i>, 1994, 4(3):159-70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1429411">
<a name="1429411"></a>Soni P, Weintraub AL. Buspirone-associated mental status changes. <i>J Am Acad Child Adolesc Psychiatry</i>. 1992;31(6):1098-1099. doi:10.1097/00004583-199211000-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/1429411/pubmed" id="1429411" target="_blank">1429411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9179637">
<a name="9179637"></a>Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. <i>Int Clin Psychopharmacol</i>. 1997;12(1):61-63. doi:10.1097/00004850-199701000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/9179637/pubmed" id="9179637" target="_blank">9179637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10356651">
<a name="10356651"></a>Sramek JJ, Hong WW, Hamid S, Nape B, Cutler NR. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. <i>Depress Anxiety</i>. 1999;9(3):131-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/10356651/pubmed" id="10356651" target="_blank">10356651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28846022">
<a name="28846022"></a>Strawn JR, Mills JA, Cornwall GJ, et al. Buspirone in children and adolescents with anxiety: a review and bayesian analysis of abandoned randomized controlled trials. <i>J Child Adolesc Psychopharmacol</i>. 2018;28(1):2-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/28846022/pubmed" id="28846022" target="_blank">28846022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29803818">
<a name="29803818"></a>Thorsness KR, Watson C, LaRusso EM. Perinatal anxiety: approach to diagnosis and management in the obstetric setting. <i>Am J Obstet Gynecol</i>. 2018;219(4):326-345. doi:10.1016/j.ajog.2018.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/29803818/pubmed" id="29803818" target="_blank">29803818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16554526">
<a name="16554526"></a>Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. <i>N Engl J Med.</i> 2006;354(12):1243-1252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/16554526/pubmed" id="16554526" target="_blank">16554526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1573045">
<a name="1573045"></a>van Laar MW, Volkerts ER, van Willigenburg AP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. <i>J Clin Psychopharmacol</i>. 1992;12(2):86-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/1573045/pubmed" id="1573045" target="_blank">1573045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9746382">
<a name="9746382"></a>Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. <i>Br J Obstet Gynaecol</i>. 1998;105(8):882-889. doi:10.1111/j.1471-0528.1998.tb10234.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buspirone-pediatric-drug-information/abstract-text/9746382/pubmed" id="9746382" target="_blank">9746382</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13102 Version 639.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
